The clinical significance of gene fusions detected by DNA-based next generation
sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors …

Tumor resistance to EGFR tyrosine kinase inhibitors (TKIs) occurs invariably, and receptor
tyrosine kinase (RTK) fusions have emerged as rare but actionable resistance mechanisms …

Resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers
(NSCLCs) with activating EGFR mutations generally involve development of acquired …

To the Editor: Gene fusions involving EGFR are rare events in cancer. 1, 2 An analysis of
10,000 cases of NSCLC profiled by Foundation Medicine (FM)(Cambridge MA) found five …

Introduction Activation of the fibroblast growth factor receptor (FGFR) family through fusion
with various partners has been described in multiple cancer types, including NSCLC. FGFR …

Methods A total of 404 NSCLC cases were screened for principal driver mutations with a
custom next-generation sequencing (NGS) panel covering 124 cancer genes using the …

Introduction Multiple genetic mechanisms have been identified in EGFR-mutant lung
cancers as mediators of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) …

While the development of EGFR-targeted tyrosine kinase inhibitors (TKIs) has revolutionized
treatment of EGFR mutation-positive non-small-cell lung cancer, acquired resistance to …

Introduction Increasing evidence leads to a ratiocination that genetic heterogeneity of the
lung adenocarcinoma with EGFR mutations may impact clinical responses and outcomes to …

Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising
the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are …